



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

Public Declaration of Interests and Confidentiality Undertaking of  
European Medicines Agency (EMA),  
Scientific Committee members and experts

Public declaration of interests

I, **Aldo Pietro Maggioni**

Organisation/Company: ANMCO Research Center, Heart Care Foundation

Country: Italy

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment

No interest declared

2.2 Consultancy

No interest declared

2.3 Strategic advisory role

No interest declared

2.4 Financial interests

No interest declared

2.5 Principal investigator

Period	Company	Products	Therapeutic Indication
06/2020-(current)	Bayer (DSMB participation)	Finerenone	Heart Failure with Preserved Ejection Fraction
01/2016-09/2022	DalCor Pharma	dalcetrapib	Cardiovascular Prevention
12/2015-11/2021	Novartis	sacubitril/valsartan	Post-Myocardial Left Ventricular Dysfunction
12/2020-(current)	AstraZeneca	ticagrelor	CV prevention
04/2021-(current)	Bayer (DSMB participation)	Finerone	Chronic Kidney Disease

Classified as public by the European Medicines Agency

2

11/2013-02/2019	Novartis	Serelaxin	Heart Failure
06/2014-12/2019	Novartis	sacubitril/valsartan	Heart Failure with Preserved Ejection Fraction

## 2.6 Investigator

No Interest Declared

## 2.7 Grant / Funding to organisation /institution

Company	Subject Matter
Daiichi Sankyo	Pulmonary Embolism
Boehringer Ingelheim	Chronic Kidney Disease
Daiichi Sankyo	Atrial Fibrillation in Cancer

## 2.8 Close family member interest

No interest declared

## 2.9 Repurposing of a medicinal product

Period	Products	Therapeutic Indication	Involvement in the repurposing
06/2015-12/2019	Colchicine	Cardiovascular Secondary Prevention	Involvement in the repurposing of a medicinal product where my organisation is collaborating with the champion of the repurposing

## 2.10 Any other interests or facts

Executive Committee member of the EuroHeart (ESC)  
 Member of the Regulatory Committee of the ESC  
 Chair of the DSMC of the SOLIDARITY WHO trial  
 Member of the DSMC of the INVICTUS Trial supported by PHRI

## 2.11 Committee for Advanced Therapies (CAT) member or alternate

Not a CAT member or alternate

**CONFIDENTIALITY UNDERTAKING**

In view of the following definitions:

Classified as public by the European Medicines Agency

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality as long as the information or document has not been made public/is not in the public domain.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.
- When expressing views to clearly indicate that the views are my own if acting in my own capacity or those of the EMA, Committee, Working Party, Expert Group or other group if acting on behalf that group.
- Not to disclose any commercially confidential information.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

Full Name:	ALDO PIETRO MAGGIONI
Date:	2022-10-11

*For Definitions of activities etc, refer to Policy on Handling of competing interests / Electronic DOI template*